

**PROFIT WARNING ON THE UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED
31 DECEMBER 2024**

The Board of Directors ("**Board**") of Cordlife Group Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that, based on a preliminary assessment of the Group's draft unaudited financial results for the financial year ended 31 December 2024 ("**FY2024**"), the Group is expected to report a loss for FY2024.

The loss is mainly attributable to:

- (i) the negative financial impact due to suspension of Singapore operations pursuant to notices from the Ministry of Health to stop the collection, testing, processing and/or storage of any new cord blood and human tissues, or the provision of any new types of tests to patients in Singapore from 15 December 2023 up to 14 September 2024;
- (ii) the conditional resumption of cord blood banking service operations in a controlled manner, such that the Company shall not collect, test, process and/or store more than 30 units per month of new cord blood from 15 September 2024 to 13 January 2025; and
- (iii) the refunds and waivers of annual fees for all affected active clients whose stored cord blood units were deemed by the Ministry of Health's expert panel to be at high risk of being adversely affected by the temperature excursions ("**High-Risk Tanks**") and recognition of contract liabilities relating to future storage obligations for all active clients in the High-Risk Tanks. As previously disclosed, the Company had estimated that this would result in a decrease in revenue and profit before tax of approximately S\$9.7 million.

The Board also refers to the Company's announcement dated 14 January 2025 in relation to the renewal of the Company's cord blood banking and human tissue banking licences ("**Licences**") for a period of one (1) year. The Company has fully resumed operations in Singapore after it was issued with the cord blood banking and human tissue banking licences which are effective from 14 January 2025 and are valid for a period of one (1) year. The Company expects an improvement in the revenue streams to be contributed by the Group's Singapore business.

However, the pace of recovery and outlook for the financial year ending 31 December 2025 remains uncertain, and there is no assurance that the Company can resume profitability in the financial year ending 31 December 2025.

The information contained in this announcement is based on the preliminary assessment by the Company's management on the unaudited financial results for FY2024 of the Group, and such financial information have not been reviewed by the Group's auditors. Further details of the Group's financial performance will be disclosed when the Company announces the Group's unaudited financial results for FY2024 on or before 1 March 2025.

In view of the foregoing, shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company. They should consult their stockbrokers, bank managers, solicitors, or other professional advisers if they have any doubt about the actions they should take. The Company will update its shareholders and the investing public if there are any material developments in relation to the above, in accordance with the requirements of the listing rules of the Singapore Exchange Securities Trading Limited.

By order of the Board

CORDLIFE GROUP LIMITED

Cheok Hui Yee
Goh Xun Er
Company Secretaries

18 February 2025